Safety assessment of Streptococcus thermophilus IDCC 2201 used for product manufacturing in Korea
- 2020-10-02
- Food Science & Nutrition 8(11)
- O-Hyun Ban
- S. Oh
- Chanmi Park
- Won Yeong Bang
- Bo Som Lee
- Soo-yeon Yang
- Seung A Chae
- Y. Jung
- Jungwoo Yang
- PubMed: 33282276
- DOI: 10.1002/fsn3.1925
Study Design
- Population
- Rats
- Methods
- In vitro and in vivo experiment.
Abstract
Safety evaluation of probiotics has become increasingly important for human consumption in food industry. The aims of this study were to assess safety of Streptococcus thermophilus IDCC 2201 through in vitro and in vivo tests. In results, this strain was found to be negative for hemolytic and β-glucuronidase activity. In addition, thermophilus IDCC 2201 was susceptible to nine antibiotics suggested by EFSA. In accordance with MIC tests, whole-genome analysis indicated that S. thermophilus IDCC 2201 neither harbors antibiotic resistance nor toxigenic genes. Furthermore, none of the biogenic amines including tyramine and histamine was produced and negligible amounts of D-lactate were produced by S. thermophilus IDCC 2201. Finally, it was confirmed that there was no mortality and toxicity throughout single-dose oral toxicity tests in rats. Therefore, we report that S. thermophilus IDCC 2201 is considered to be safe for human consumption as probiotics.
Keywords: Antibiotic resistance; Probiotics; Safety evaluation; Single‐dose oral toxicity; Streptococcusthermophilus.